The two big issues that I see for this company:
1- Thematic risk. Overall med tech is struggling big time. Look at the US listed biotech ETFs and some of the large pharms and they are getting crushed. Some
ETFs are done 50%. Also specy companies like this will get sold off the hardest in any bear market.
2- pandemic becoming a more manageable endemic. The longer management delay and fluff around with the testing, the less of a chance, that the world will need an antiviral treatment for covid. Unfortunately, imo the co’s progress is about 12-18 months too late on the covid front. Also this company is shocking slow on everything it does. Whether that’s management or cash flow, I don’t know. Shame, should have done better.
still has its bread and butter, HIV. Which is its better bet imo
The two big issues that I see for this company:1- Thematic risk....
-
- There are more pages in this discussion • 3,975 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.14M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.9¢ | $7.664K | 403.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1202498 | 5 |
View Market Depth
| Last trade - 13.42pm 27/09/2024 (20 minute delay) ? |
| BIT (ASX) Chart |